You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Patient baseline characteristics

From: Carbon ion therapy (C12) for high-grade malignant salivary gland tumors (MSGTs) of the head and neck: do non-ACCs profit from dose escalation?

Patient baseline characteristics
   All  
   pts %  
histology mucoepidermoid carcinoma 18 45  
  adeno carcinoma 8 20  
  acinic cell carcinoma 3 8  
  squamous cell carcinoma 2 5  
  salivary duct carcinoma 2 5  
  NOS 2 5  
  basal cell-adeno carcinoma 2 5  
  adenosquamous carcinoma 1 3  
  myoepithelial carcinoma 1 3  
  basaloid carcinoma 1 3  
stage T 1 3 8  
  T 2 5 13  
  T 3 13 33  
  T 4a 10 25  
  T 4b 7 18  
  T 4c 1 3  
  unknown 1 3  
  N+ 16 40  
  M1 3 8  
treatment for recurrent disease   7 18  
site parotid gland 20 50  
  submandibular gland 5 13  
  oropharynx 3 8  
  maxilla 2 5  
  palate 2 5  
  lacrimal gland 2 5  
  paranasal sinus 2 5  
  petrous bone 2 5  
  middle ear 1 3  
  nasopharynx 1 3  
age median in years [range] 60 35-80  
follow-up all, median in months [range] 25.5 2.5-58.4  
  alive, median in months [range] 27.3 3-58.4  
target volume CTV1 (boost) in ml 120 34-564  
  CTV2 (extended target volume) in ml 424 105-1538  
dose C12 in GyE [range] 23.95 17.4-24.4 2 pts: C12 only with 66 GyE
  IMRT in Gy [range] 50 42-56.4  
  total in GyE [range] 74 50.4-74.8